Necitumumab

Necitumumab

Necitumumab Fab (blue) bound to EGFR (green). PDB: 6B3S​
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	EGFR
Clinical data
Trade names	Portrazza
AHFS/Drugs.com	Multum Consumer Information
License data	US DailyMed: Necitumumab
Routes of administration	Intravenous infusion
ATC code	L01FE03 (WHO)
Legal status
Legal status	CA: ℞-only[2] US: WARNING[1]Rx-only[3]
Pharmacokinetic data
Elimination half-life	~14 days
Identifiers
CAS Number	906805-06-9^N
DrugBank	DB09559^Y
ChemSpider	none
UNII	2BT4C47RUI
KEGG	D10018^N
Chemical and physical data
Formula	C6436H9958N1702O2020S42
Molar mass	144844.87 g·mol^−1
^NY (what is this?)  (verify)

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[4] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[5][6][3] It was counterproductive in non-squamous non-small-cell lung carcinoma.[3][7]

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
3. "Portrazza- necitumumab solution". DailyMed. 15 December 2023. Retrieved 26 October 2024.
4. International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
5. Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28.
6. "Necitumumab". Approved Drugs. U.S. Food and Drug Administration. Archived from the original on 2017-01-11. Retrieved 2019-12-16.
7. Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.